Abstract Aim of the work: To evaluate the cardiovascular findings in Behc¸et's disease (BD) and assess the levels of vascular endothelial growth factor (VEGF) to study its relation to the extent of cardiovascular involvement.
Introduction
Behc¸et's disease (BD) is a systemic disorder of recurrent acute inflammation characterized by major symptoms: aphthous ulcers, genital ulcers, uveitis and skin lesions. Involvement of intestines, vessels and CNS system sometimes leads to poor prognosis [1] . It is considered as a nonspecific systemic vasculitis of small and large vessels involving both venous and arterial sides, [2] with particular systemic features including thrombotic events. Venous thrombosis can be seen in any vein with a thrombus sticky to the inflamed vessel wall. Arterial involvement is seen less frequently and can result in true and/or false aneurysms or less frequently a thrombotic occlusion [3] . The precise pathogenic mechanism underlying the thrombotic tendency in BD is still obscure, but vasculitic endothelial cell injury and/or dysfunction which results from immune-mediated inflammatory infiltrate with hypofibrinolysis have been suggested to play crucial roles [4] .
Vascular endothelial growth factor (VEGF) is a glycoprotein with similarity to platelet derived growth factor. It is a potent cytokine that modulates angiogenesis by acting as an essential mitogen for vascular endothelial cells. Because VEGF is a potent mitogen for dermal and ocular microvascular endothelial cells, its expression may be important in the vascular bed of Behcet's patients [5] .
Cardiac involvement is among the most life-threatening complications in BD but its incidence and nature are not yet clearly documented [6] . Mortality of this complication is relatively high (around 20%). In addition cardiac involvement in BD can be seen frequently without symptoms [7] . The spectrum of cardiac disease, according to reported cases in the literature, may include pericarditis, coronary artery stenosis or aneurysm, myocarditis, cardiomyopathy, congestive heart failure, valvular pathology, endocarditis, intracardiac thrombosis, and aneurysm of aorta or its branches [8] . In this regard, it is of great importance to delineate the cardiovascular involvement in BD [9] .
The present study aimed at evaluation of the cardiovascular findings in patients with Behcet's disease and assessment of their serum levels of vascular endothelial growth factor (VEGF) in order to study its relation to the extent of cardiovascular involvement.
Patients and methods
Thirty Egyptian patients diagnosed as BD were included in this study. All patients have fulfilled the International Study Group criteria for Behc¸et's disease, [10] randomly recruited from the Ain Shams University Hospital internal medicine department and rheumatology outpatient clinic between December 2011 and December 2012. They were all free of any cardiovascular symptoms. Twenty healthy age and sex matched volunteers served as controls. A verbal consent was obtained from all subjects participating in this study, after explaining its nature. The study was approved by the Ain Shams local ethics committee.
Exclusion criteria
Patients with evidence of pre-existing cardiac and/or vascular affection due to diseases other than Behc¸et's disease, together with cases of diabetes mellitus were excluded from this study.
Clinical assessment
À Full history taking and clinical examination at time of inclusion into the study, and this clinical assessment included cardiac examination, dermatological examination for all skin lesions and professional ocular examination. The disease activity was assessed using Behc¸et's Disease Current Activity Form (BDCAF) score. Patients with BD were categorized as active (total activity score P 5) or inactive (total activity score < 5) [11] . The probability of error at 0.05 was considered significant; while at 0.01 and 0.001 are highly significant.
Laboratory assessment

Results
The present study included thirty Behcet's disease (BD) patients (Group I) with an age ranging from 20 to 52 yr (30.6 ± 9.36 years), and the male to female ratio was 4:1 (24 males and 6 females). Twenty age and sex matched healthy volunteers served as controls (Group II). Their ages ranged from 19 to 47 yr (26.9 ± 8.38 years) with a male to female ratio 4:l (16 males and 4 females).
The general features and clinical manifestations of the studied BD patients (Group I) are displayed in Table 1 .
Twelve patients (40%) had vascular complications of the 12 patients with vascular involvement, 3 (25%) patients had only DVT, 2 (16.7%) patients had only large vein thrombosis (SVC and IVC), 2 (16.7%) patients had both deep and large veins thrombosis, and 2 (16.7%) patients had both DVT and cardiac lesions. Arterial events were evident in 3 patients (10%); arteritis associated with aneurysm formation {two patients (6.7%) showed pulmonary artery aneurysms and one (3.3%) patient had femoral artery aneurysm}.
Eight patients (26.7%) had cardiac involvement. There was a high prevalence of mitral valve affection (5 patients-16.3%) in the form of mitral regurge (4 patients-13.3%) and mitral valve prolapsed (one patient-3.3%).Other cardiac complications were in the form of aortic regurge (one patient-3.3%) NB: this patient had also mitral regurge, tricuspid regurge (one patient-3.3%), antro-septal myocardial infarction (one patient-3.3%), and right ventricular thrombus with right bundle branch block (RBBB) (one patient-3.3%). This patient with right ventricular thrombus and RBBB was treated with oral anticoagulant, steroids, azathioprine and cyclosporine therapy with complete resolution of the thrombus within 2 months.
On comparing BD (Group I) with the controls (Group II) the Hg, ESR, CRP, cholesterol, triglycerides, low density lipoprotein (LDL-C) and serum creatinine levels in all patients were significantly higher than that of the controls (p < 0.001, and/or p < 0. 01), while the serum level of high density lipoprotein (HDL-C) in all patients was significantly lower than that of the controls (p < 0.001). The VEGF levels of the patients were highly significantly higher than those of the healthy controls (p < 0.001) ( Table 2) .
According to the presence or absence of cardiac and vascular manifestations BD patients (Group I) were further classified into two subgroups: À Group Ia includes the patients with cardio-vascular affection (10 patients had only vascular lesions, 6 patients had only cardiac lesions, and 2 patients had both vascular and cardiac lesions {total n = 18}). À Group Ib includes the patients without cardio-vascular affection (12 patients).
On comparing the subgroups; group Ia and group Ib as regards the clinical manifestations of BD, genital ulcers and joint affection were significantly higher in Group Ia (88.9% vs 58% and 50% vs 16.7%, respectively) (p < 0.05), while eye lesions were significantly higher in Group Ib (66.7% vs 22.2%) (p < 0.05). (Table 3) .
The patients' age was significantly higher in group Ia (p < 0.001), while no significant difference was found concerning disease duration (p > 0.05).
The frequency of male sex was significantly higher among the patients of group Ia {16 (88.9%) males vs. 2 (11.1%) females}, than group Ib {8 (66.7) males vs. 4 (33.3%) females} (p < 0.05). The BD activity score was also, significantly higher among the patients of group Ia (p < 0.01).
Serum levels of cholesterol, triglycerides, low density lipoprotein (LDL-C) in the subgroup Ia patients were significantly higher than that of the subgroup Ib patients (p < 0.001), while the ESR, CRP and serum levels of high density lipoprotein (HDL-C) showed no significance difference between both subgroups Ia and Ib (p > 0.05). Serum level of VEGF shows highly significant difference between subgroups Ia and Ib being higher in group Ia (p < 0.01). (Table 4 ). The highest VEGF levels were recorded among BD patients with combined cardiac and vascular lesions (481.7 ± 222.4 pg/ml), followed by those with isolated cardiac lesions (330.5 ± 141.5 pg/ml), and lastly patients with isolated vascular lesions (310.4 ± 101.2 pg/ml). VEGF levels also had a significant positive correlation with Behc¸et's Disease Current Activity Form (BDCAF) score among the subgroup Ia (r = 0.783, p = 0.001) and subgroup Ib (r = 0.981, p = 0.001).
The difference between the group I and II was statistically significant as regards all echo-cardiographic values except for inter ventricular septum diameter (IVSD). (Table 5 ).
The ratio of the mitral inflow velocities (E/A ratio) which indicates left ventricular diastolic dysfunction also was statistically significantly lower in the group I (p < 0.01) ( Table 6 ).
Discussion
Behc¸et's disease (BD) is a multi-systemic, chronic, inflammatory disorder of unknown etiology. The incidence and natural history of cardiac involvement in this disorder are not yet clearly documented. Cardiovascular manifestations have been reported in 7-40% of patients in the literature. As nearly 8% of these will have serious complications during follow-up, identification of the cardiovascular lesions is important [12] .
Vascular involvement in BD develops within 10 years of the initial diagnosis. The first 2 years of the disease are the most critical period. Vascular involvement is more frequent in men; the reported male:female ratio is 5.6:1 [13] . In our study, the mean age of the BD patients with cardiovascular involvement was 37.4 ± 9.75 years and the male:female ratio was 8:1.
Although any large or small arteries or veins may be involved in BD, venous lesions are the predominant vascular lesions. In the present study the incidence of the vascular involvement was reported to be 40% (12/30) of the cases. This result is in accordance to the result of Gu¨l et al [14] who reported the occurrence of vascular affection in 43% (13/30 patients) that was much higher than the result of Tohme et al. [15] who reported the occurrence of vascular affection in 13% only of the studied cases (18/140 patients).
Out of the 12 patients with vascular involvement, 9 (75%) patients had venous lesions, and 3 (25%) patients had arterial lesions, but none of our patients had both arterial and venous lesions. These results partially disagree with Ko et al. [16] who reported the occurrence of vascular lesions in 51.7% (33/64), but they showed a relatively equal incidence of venous (36%), arterial (33%) and combined arterial and venous (30%) involvement. The causes of this discrepancy may be related to the ethnic and environmental factors that may modulate the expression of BD in different geographical areas.
Two out of the 3 patients with arterial aneurysm showed pulmonary artery aneurysms. This finding comes in accordance with Marzban et al., [8] who reported that pulmonary artery aneurysm is one of the most common forms of great artery involvement in BD.
Heart involvement with frank clinical presentation is rare in BD. It was reported as 1-5% in a case series while it was 16.5% in a registry of Behc¸et autopsy cases in Japan [17] . Sporadic cases of endocarditis, myocarditis, pericarditis, acute myocardial infarction, aortic aneurysm, ventricular thrombosis, congestive cardiomyopathy, and valvular dysfunction have been reported [18] .
In our study cardiac involvement was detected in eight patients (26.7%) in the form of endocardial involvement presented with mitral valve insufficiency (4/8), mitral valve prolapse (1/8), aortic insufficiency (1/8) and tricuspid insufficiency (1/8). These results agreed with the results of Gu¨l et al [14] who detected minimal mitral and tricuspid valve insufficiencies, mitral valve prolapse and mild pulmonary hypertension in (10/30) 33% of BD patients. Gurgun et al. [18] detected mitral valve prolapse in 25%, mitral regurgitation in 40% and aortic valve prolapse in 5% of BD patients [18] . The etiology of valve prolapse in BD can be attributed to systemic vasculitis and tissue derangement [12] .
Also, in the present study we detected the presence of right ventricular thrombus with right bundle branch block in one patient. This patient was treated with oral anticoagulant, steroids, azathioprine and cyclosporine therapy with complete resolution of the thrombus within 2 months. Many cases with intracardiac thrombosis (ICT) were reported as complication of BD [19] [20] [21] [22] [23] and are usually located in the right side of the heart, mainly the right ventricle. The reason for predilection to involve right ventricular is still unclear. Thromboses involving both ventricles or limited only to the left ventricle have been also described [14] . Based on autopsy findings, it looks that endomyocardial fibrosis plays a role in the ICT development in some patients [24] , but it is not clear whether they are secondary to underlying endocarditis or endomyocardial fibrosis, because in some case reports, a normal underlying myocardium was described [25] .
Coronary artery disease (CAD) is rare in BD. It can be manifested clinically as myocardial infarction, silent ischemia, and stable or unstable angina. Coronary occlusion is attributed to fibrous intimal thickening as a result of local vasculitis [26] . In agreement with this previous finding, the coronary angiography of our BD patient with antro-septal myocardial infarction was normal without any atherosclerotic changes. Left ventricular diastolic dysfunction (E/A mitral Doppler flow pattern < 1) was detected in 14 (46.7%) of our studied Behc¸et patients and only 2 (10%) of the controls. This finding agreed with the result recorded by Konomidis et al. [27] .
VEGF is an endothelial-cell specific potent angiogenetic factor and a marker for endothelial dysfunction. VEGF stimulates inflammation, angiogenesis, microvascular hyper-permeability and endothelium-dependant vasodilatation as well as endothelium nitrous oxide (NO) production [28] . Endothelial dysfunction due to anti-endothelial cell antibodies and elevated plasma levels of VEGF leads to disturbance of microcirculation, increased blood viscosity and abnormal blood flow [29] . Previous studies reported high plasma levels of VEGF in Behcet's syndrome [30] , BD with acute thrombosis [29] , and in BD patients with neuro-Behcet's [31] .
In our study the serum levels of VEGF were detected to be significantly higher in BD patients than the controls. On further classifying the BD patients according to the presence of cardiovascular lesions we found that the highest levels were recorded among BD patients with combined cardiac and vascular lesions, followed by those with isolated cardiac lesions, and lastly patients with isolated vascular lesions. All patients with cardiovascular lesions were merged into one subgroup (Ia) to allow reasonable statistical comparison. The subgroup Ia had significantly higher serum levels of VEGF than the subgroup Ib who had no cardiovascular lesions. The disease activity score was significantly higher among the patients of the subgroup Ia, this can be explained by the higher incidence of combination with other disease manifestations.
Our results showed a significant positive correlation between the serum levels of VEGF and the disease activity score among both BD subgroups Ia and Ib. This finding occurred in accordance with the results of Cekmen et al., [32] .But, disagreed with Erdem et al., who reported that the serum levels of VEGF showed no difference between active and inactive cases of their studied BD [33] .
In the present study, BD patients had a high atherogenic potential as marked by the significantly lower HDL, and higher LDL, cholesterol and triglycerides concentrations compared to controls. On further comparison BD patients of the subgroup Ia had higher LDL, cholesterol and triglycerides concentrations compared to patients in the subgroup Ib, but no statistical difference was detected as regards HDL. In agreement with our finding some previous studies reported that BD patients had atherogenic lipid profile [34] [35] [36] . But in two other studies while investigating the risk of atherosclerosis in patients with BD, blood lipid levels were not significantly different from the levels found in the healthy population [37] [38] . Recently one study surprisingly reported low blood lipid levels as a protector against atherosclerosis in BD [39] . This may give a new insight that the inflammation, lipid profile and the development of atherosclerosis in BD may develop through a different mechanism from that associated with other inflammatory conditions.
In conclusion, cardiovascular findings are not uncommon in BD, but frank clinical presentation is rare. So, screening of the cardiovascular system in all patients with BD even if there is no clinically apparent cardiovascular disease (ECG, echocardiography, and vascular Doppler with extended investigations as needed) might unmask silent cardiovascular lesions for early and proper intervention. High serum levels of VEGF in BD patients with cardiovascular involvement, suggests a role for VEGF in the cardiovascular etiopathogenesis of the disease, so it can be used as therapeutic targets.
Recently, several anti-VEGF drugs have been approved by the food and drug administration (FDA) for clinical use [40] . Further clinical trials may be recommended to assess the efficacy of anti-VEGF drugs as mono-therapy or as part of combination regimens in BD with cardiovascular lesions. 
